Spyre Therapeutics (SYRE) Gains from Sales and Divestitures (2015 - 2018)
Spyre Therapeutics (SYRE) reported Gains from Sales and Divestitures of $21645.0 for Q4 2018, down 33.58% quarter-over-quarter from $32588.0 in Q4 2015.
Spyre Therapeutics (SYRE) Gains from Sales and Divestitures (2015 - 2018) Analysis & Trends
Spyre Therapeutics has reported Gains from Sales and Divestitures for 2 years, with the latest figure at $21645.0 in Q4 2018.
- For the quarter ending Q4 2018, Gains from Sales and Divestitures changed N/A year-over-year to $21645.0; the trailing twelve-month figure through Dec 2018 stood at $21645.0 (changed N/A YoY), and the FY2018 full-year result was $21645.0, changed N/A from the prior year.
- Gains from Sales and Divestitures for Q4 2018 stood at $21645.0, down from $32588.0 in the prior quarter.
- The five-year high for Gains from Sales and Divestitures was $32588.0 in Q4 2015, with the low at $21645.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Spyre Therapeutics | 6.95 Bn | 6.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 21,645.00 |
| Dec 31, 2018 | 21,645.00 |
| Dec 31, 2015 | 32,588.00 |
| Dec 31, 2015 | 32,588.00 |